Assessing treatment response according to the genetic aetiology has been investigated in patients with early‐onset low‐turnover osteoporosis due to WNT1 or PLS3 mutations who were shown to respond to teriparatide therapy 61. The gene discussed is PLS3; the disease is osteoporosis.